 The FDA has extended the review period for CTI BioPharma Corps NASDAQ: CTIC pacritinib marketing application for myelofibrosis. The application for pacritinib covers adult patients with intermediate or high-risk primary or secondary post-polycythemia vera or post-essential thrombocythemia myelofibrosis with a baseline platelet count of over 50 × 109L. 